ESPOO, Finland, 23rd June, 2015 – Picosun Oy, the leading supplier of high quality Atomic Layer Deposition (ALD) technology for industrial manufacturing, provides the advanced ALD coating solutions to enable the next generation of cutting-edge medical technology.
ALD’s unique ability to form perfectly hermetic but still ultra-thin encapsulation layers to cover even the smallest, most complex surface details and particles is an invaluable asset to the medical equipment and medicine manufacturers. It increases the operational life, reliability, and safety of the equipment and enables advanced synthesis, delivery, and dosing of medical substances. Several ALD materials are naturally biocompatible and, as a gas-phase, low temperature method, ALD allows coating of sensitive substrates such as plastics and polymers – key materials in various medical devices.
“Incorporation of our ALD solutions into the field of medical technology opens up an interesting new market for us. ALD-enabled medical innovations already create growth and success for our customers – an example being recently stock listed Nanexa AB in Sweden, which utilizes our ALD technology in production of nanofabricated drug delivery systems. In InForMed, one of our new, inter-European ECSEL projects we cooperate with the leading industries in the field. We are excited to see our ALD expertise realize the most advanced, better, safer, and patient-friendly diagnostics and treatment equipment,” states Juhana Kostamo, Managing Director of Picosun.
Picosun provides the most advanced ALD thin film technology and enables the industrial leap into the future by novel, cutting-edge coating solutions, with four decades of continuous expertise in the field. Today, PICOSUN™ ALD systems are in daily production use in numerous major industries around the world. Picosun is based in Finland, with subsidiaries in USA, China, Taiwan, and Singapore, and a world-wide sales and support network.
The project InForMed (An integrated pilot line for micro-fabricated medical devices), running from 1st June 2015 to 31st May 2018 is financed by ECSEL Joint Undertaking.